

Online appendix, Table A. Hyperglycemic clamp baseline characteristics

	Non-carriers	Carriers	P-value
N	8	8	
Age (years)	54 ± 11	52 ± 12	0.78
Men, n (%)	4 (50%)	4 (50%)	1.00
Body mass index	24.5 ± 3.2	25.1 ± 3.0	0.68
Cholesterol (mmol/L)			
total	5.05 ± 1.38	4.47 ± 0.57	0.30
LDL	3.10 ± 1.13	3.28 ± 0.52	0.70
HDL	1.62 ± 0.38	0.65 ± 0.39	<0.001
Triglycerides (mmol/L)	0.76 [0.50-0.92]	0.90 [0.65-1.92]	0.28
Fasting glucose (mmol/L)	4.7 ± 0.6	4.7 ± 0.5	0.88
Fasting insulin (pmol/L)	45 ± 26	34 ± 20	0.33
Fasting glucagon (pmol/L)	54 ± 12	49 ± 20	0.52
HbA1c (%)	5.5 ± 0.3	5.5 ± 0.5	0.99
History of CAD, n (%)	0 (0)	2 (25)	0.45
History of DM	0 (0)	0 (0)	N/A
Family history of DM	1 (13)	0 (0)	0.86
Smokers, n (%)	1 (13)	1 (13)	1.0
Medication use, n (%)			
Statins	1 (13)	4 (50)	0.14
HRT	0 (0)	0 (0)	N/A
Thiazides	0 (0)	0 (0)	N/A
Beta-blockers	1 (10)	1 (10)	1.00

Baseline characteristics of participants in hyperglycemic clamping experiment. Data are presented as means ± SD, number (%) or median [interquartile range]. CAD = coronary artery disease, HRT = hormone replacement therapy.